CA-ARIBIO-CO.,-LTD.
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 15:15:00 CET | Press release
The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause
Amazfit Introduces Active Max: Bigger, Brighter, and Built for Maximum Performance30.12.2025 09:00:00 CET | Press release
The newest member of the Active family blends new design, expanded storage, and longer battery to help users train smarter and reach their goals with confidence. Amazfit, a leading global smart wearable brand by Zepp Health (NYSE: ZEPP), today announces the Amazfit Active Max, the newest member of the Amazfit Active family. Built for everyday athletes and anyone looking to elevate their wellness routine, Active Max blends a 1.5″ ultra-bright AMOLED display, up to 25 days of battery life, easy podcast listening and advanced training tools to support consistent training and clearer visibility across any activity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230279762/en/ Bigger Display. Max Clarity: A 1.5″ ultra-bright AMOLED display delivers exceptional clarity in any setting—whether in the gym, outdoors, or on the move. With up to 3,000 nits of peak brightness, the screen ensures real-time stats are always easy to read.
2026 Future of Fitness Report: Experts from Coherent Solutions Turn Years of Fitness Industry Software Engineering Work Into a Guidebook on Future-proof Digital Transformation in Fitness29.12.2025 18:48:00 CET | Press release
Coherent Solutions has released its 2026 Future of Fitness report, capturing years of domain knowledge from helping emerging and global fitness brands drive digital transformation, innovate, and improve member engagement. “The Future of Fitness: Winning with Digital Value Creation” takes lessons from real projects and fitness enthusiasts, turning them into a guidebook for the next era of fitness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251229965712/en/ New Fitness Tech Whitepaper by Coherent Solutions While the global fitness market is on track to surpass $257 billion, and brands are expanding globally, pioneering new regions, and implementing new technologies, the report highlights the most effective growth trajectory in acknowledging the importance of technology as equal to supporting the fitness community. "Most people only spend 3–5 hours a week in a gym. That leaves 160+ hours where their choices and habits are i
Hanshow and the University of Cambridge Launch Joint Research on Augmented Intelligent Hybrid Wireless Technology25.12.2025 12:34:00 CET | Press release
Hanshow, a global leader in electronic shelf labels (ESL) and digital store solutions, has entered into a multi-year research collaboration with the University of Cambridge, one of the world’s most prestigious academic institutions. The partnership will focus on joint research and innovation in next-generation intelligent hybrid wireless technologies, marking an important milestone in Hanshow’s continued investment in core technologies and long-term innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251225988816/en/ This collaboration leverages the University of Cambridge’s deep expertise in fundamental wireless technology research, alongside Hanshow’s extensive industry experience, to further strengthen multi-protocol integration capabilities and expand scalable applications across diverse retail scenarios. Guided by shared principles of innovation, collaboration, openness, and knowledge sharing, the two parties aim
Social Development Bank Highlights Strategic Partnerships and Global Initiatives at DeveGo 202524.12.2025 17:27:00 CET | Press release
The forum held in Riyadh witnessed the signing of 51 agreements aimed at strengthening the entrepreneurial ecosystem The Social Development Bank (SDB) hosted the second edition of the Entrepreneurship and Modern Business Practices Forum, “DeveGo 2025”, from 21 to 23 December in Riyadh. Held under the patronage of His Excellency Eng. Ahmed bin Sulaiman Al Rajhi, Minister of Human Resources and Social Development and Chairman of SDB’s Board of Directors, the forum brings together government leaders, global experts, investors, and entrepreneurs to shape the future of entrepreneurship and modern business practices in the Kingdom of Saudi Arabia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251224036724/en/ From right to left: Ahmed Al Rajhi, Saudi's Minister of Human Resources and Social Development, H.E. Rebeca Grynspan, Secretary-General of UNCTAD, and Sultan Al Hamidi, CEO of Social Development (Photo: AETOSWire) Opening th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom